 |
Andrew
F. Leuchter, M.D. Professor and Vice Chair of the Department of Psychiatry and Biobehavioral Sciences, at the David Geffen School of Medicine, UCLA; Director, Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute and Hospital |
|
Contact Information UCLA Department
of Psychiatry & Behavioral Sciences
Biosketch
In his role as Director of Adult Psychiatry, Dr. Leuchter oversees teaching, clinical care, and clinical research of adult patients with depression, psychosis, anxiety, and other mental illnesses throughout UCLA Medical Center. He also serves as Chief of Staff for the UCLA Neuropsychiatric Hospital, and Director of Continuing Education for the UCLA Neuropsychiatric Institute. Dr. Leuchter received his undergraduate degree from Stanford University, and his medical degree from the Baylor College of Medicine. He completed his residency at the UCLA Neuropsychiatric Institute, and a Robert Wood Johnson Fellowship in the UCLA Department of Medicine. Dr. Leuchter's clinical expertise is in the treatment of depression, with a special focus on treatment-resistant and late-life depression. The thrust of his research is the enhancement of treatment outcomes in depression. He uses brain imaging techniques such as quantitative electroencephalography (QEEG), magnetic resonance imaging (MRI), and positron emission tomography (PET) to examine brain function and predict which treatments are most likely to benefit individual patients. His research program combines clinical trials with neurophysiologic and brain imaging studies to inform clinical practice in the treatment of depression. Dr. Leuchter is Board Certified in Psychiatry, has Added Qualifications in Geriatric Psychiatry and is Board Certified in Electroencephalography. He is the author of numerous articles and chapters on the assessment and treatment of depression, dementia and other major mental illnesses, and is the author of two patents for new methods to analyze brain electrical activity.
Selected References
Leuchter A, et al. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Research: Neuroimaging. 1999; 90:125-140. Cook I, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002; 27(1):120-131.
|
|